B-Lymphoblastic Leukemia / Lymphoma · Tisagenlecleucel CD19 CAR-T for R/R B-ALL ≤25 years

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	aggressive
Linked regimen	`REG-TISAGENLECLEUCEL-B-ALL`

ID	`IND-B-ALL-3L-TISAGENLECLEUCEL`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-B-ALL`
Sources	`SRC-ELIANA-MAUDE-2018` `SRC-NCCN-BCELL-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive-track 3L+ for R/R pediatric / young-adult B-ALL. Ukraine access constraint dominant — international referral pathway. Adult B-ALL (>25) → brexucabtagene autoleucel (Tecartus) separate Indication.

Used By

Algorithms

ALGO-B-ALL-2L - ALGO-B-ALL-2L